SRF617 + pembrolizumab + gemcitabine + albumin-bound paclitaxel

A four-drug combination used in cancer therapy, particularly being explored for advanced or metastatic solid tumors (notably pancreatic ductal adenocarcinoma). - **SRF617** is a monoclonal antibody targeting CD39 (ectonucleotidase), designed to block adenosine production in the tumor microenvironment and enhance immune response. - **Pembrolizumab** is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, thereby acting as an immune checkpoint inhibitor and reactivating antitumor immunity. - **Gemcitabine** is a nucleoside analog used as an antimetabolite chemotherapeutic that interferes with DNA synthesis. - **Albumin-bound paclitaxel (nab-paclitaxel)** is a nanoparticle formulation of paclitaxel bound to albumin, improving drug delivery and reducing hypersensitivity; it acts as a microtubule inhibitor. The combination is being clinically tested for safety and efficacy in advanced solid tumors, including as first-line therapy in advanced pancreatic cancer in a quadruplet regimen. The combination aims to leverage immune modulation (SRF617, pembrolizumab) with cytotoxic chemotherapy (gemcitabine, nab-paclitaxel) to improve response in difficult-to-treat cancers[5][7].

Brand names

Abraxane

Other names

anti-CD39 antibody + pembrolizumab + gemcitabine + nab-paclitaxel